. 2018 Sep 11;9:2056. doi: 10.3389/fimmu.2018.02056

Table 8.

List of in vivo studies in which the therapeutic potential of the administration of hMSCs for the treatment of autoimmune visual and auditory disorders was evaluated.

References	Autoimmune disease	Source of hMSC	Variables	Experimental model	Clinical effects	Mechanism proposed
(163)	Autoimmune uveitis	Bone marrow	None	Mice	↓Histological disease score	↑MHC class II^loLy6G⁻Ly6C^hiCD11b⁺ cells in draining lymph nodes ↓CD4⁺ cell proliferation ↑CD4⁺ cell apoptosis ↓CD4⁺IFN-γ⁺ Th1 cells ↓CD4⁺IL-17⁺ Th17 cells
(81)	Autoimmune uveitis	Embryonic stem cells	None	Mice	↓Fundoscopic score ↓Histological disease score	↓T-cell proliferation ↓CD83 up-regulation in dendritic cells ↓IL-12 ↑CD4⁺CD25⁺FoxP3⁺ Treg cells
(150)	Autoimmune uveitis	Bone marrow	None	Mice	↓Autoimmune uveitis incidence ↓Histological disease score ↑Cumulative survival rate of corneal grafts	↑MHC classII⁺B220⁺CD11b⁺IL-10⁺ monocytes and macrophages with T-cell–suppressive activities
(151)	Autoimmune hearing loss	Adipose tissue	None	Mice	↓Auditory brainstem responses threshold ↓Cochlear pathology	↓Proliferation of antigen-specific Th1 cells ↓Proliferation of antigen-specific Th17 cells ↑IL-10 production in splenocytes ↑Generation of antigen-specific CD4⁺CD25⁺Foxp3⁺ Treg cells

Both the methodology employed and the results obtained by each article are represented in this table.